Newcastle University

MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts

Retrieved on: 
星期四, 三月 7, 2024

OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.

Key Points: 
  • OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.
  • Dr. Jon Rees, Chief Executive Officer of MitoRx, said, “We are thrilled to welcome Dr.
  • Le Guiner, Dr. Filipovic, Professor Hansbro, and Professor Aartsma-Rus, to our Scientific Advisory Board.
  • She has a visiting professorship at the John Walton Muscular Dystrophy Research Center at the UK’s Newcastle University.

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Retrieved on: 
星期三, 二月 14, 2024

“Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”

Key Points: 
  • “Beyond Symptomatic Treatment of Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”
    GBA-associated Parkinson’s Disease & other Synucleinopathies: current unmet medical needs and needed therapies.
  • Discussion of recent in vivo data for GT-02287 as a best-in-class small molecule, for the treatment of GBA-Parkinson’s Disease and other neurodegenerative diseases.
  • His research interests are focused on the understanding of the molecular mechanisms of neurodegenerative diseases such as Parkinson’s, Huntington’s, and Alzheimer’s disease.
  • He is Chair of the Task Force on the Biological Definition of Parkinson’s Disease of Internation Parkinson and Movement Disorder Society.

Moa Technology hires for further growth with expansion of its leadership team – announcing appointment of CFO and US-based CBO to support advancement of next-generation herbicides

Retrieved on: 
星期一, 十一月 20, 2023

He has extensive experience of helping biotech companies raise funding, both through equity funding and industry collaborations.

Key Points: 
  • He has extensive experience of helping biotech companies raise funding, both through equity funding and industry collaborations.
  • His appointment also reflects Moa’s use of cutting-edge biotechnology processes to identify, understand and develop next-generation herbicides with game-changing speed and accuracy.
  • Without effective herbicides, farmers can lose up to 40% of their crop yield as a result of weed growth.
  • Dr. Virginia Corless, Chief Executive Officer of Moa Technology, says:
    “Moa is tackling a major crisis that threatens farmers’ livelihoods and global food security.

Moomoo's Parent Company Futu Holdings Announces US$338.5 M in Revenues and US$147.9 M Non-GAAP Net Income for Q3 2023

Retrieved on: 
星期四, 十一月 23, 2023

PALO ALTO, Calif., Nov. 23, 2023 /PRNewswire/ -- Moomoo's parent company Futu Holdings Ltd. ("Futu" or the "Company"), a leading tech-driven online brokerage and wealth management platform reported unaudited Q3 2023 earnings with US$338.5 million in revenues, up 36.2% year-over-year ("yoy"), and US$147.9 million in non-GAAP net income, a 43.7% yoy increase.

Key Points: 
  • PALO ALTO, Calif., Nov. 23, 2023 /PRNewswire/ -- Moomoo's parent company Futu Holdings Ltd. ("Futu" or the "Company"), a leading tech-driven online brokerage and wealth management platform reported unaudited Q3 2023 earnings with US$338.5 million in revenues, up 36.2% year-over-year ("yoy"), and US$147.9 million in non-GAAP net income, a 43.7% yoy increase.
  • In August, Standard & Poor's ("S&P") reaffirmed Futu's long-term issuer credit rating "BBB-", endorsing the firm's strong capital structure and effective risk management.
  • Moomoo, a leading global financial service brand of Futu, operates across the US, Singapore, Australia, Japan, Canada and beyond.
  • During the third quarter, moomoo launched US stock trading services in Japan and Canada, marking a major step in its global expansion journey.

Verde AgriTech Advances into phase 2 of Musk-Backed $100M XPRIZE Carbon Removal Challenge

Retrieved on: 
星期一, 十月 16, 2023

SINGAPORE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) is pleased to announce that it has successfully advanced to Phase 2 of the largest incentive prize in history, XPRIZE "$100M Carbon Removal" Challenge (the “Challenge”).

Key Points: 
  • SINGAPORE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) is pleased to announce that it has successfully advanced to Phase 2 of the largest incentive prize in history, XPRIZE "$100M Carbon Removal" Challenge (the “Challenge”).
  • This challenge seeks innovative solutions to extract and sequester carbon dioxide from the atmosphere, fighting climate change and rebalancing Earth’s carbon cycle.
  • “We are thrilled to be recognized by XPRIZE for our pioneering efforts in carbon removal.
  • We are confident that Verde is an outstanding candidate within the XPRIZE Carbon Removal Challenge, not only to our innovative solution, but for the potential of massive scalability”, stated Cristiano Veloso, Verde’s Founder and CEO.

Verde appoints Vice President of Corporate Development

Retrieved on: 
星期二, 十月 10, 2023

SINGAPORE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) is pleased to announce Lucas Brown as the new Vice President of Corporate Development. Mr Brown will lead Verde’s expansion into the carbon market, in addition to overseeing the Company’s institutional and investor relations. Lucas Brown has dedicated a decade working in Brazil, in the last four years serving as the British Consul to Minas Gerais state. In this role, he was responsible for diplomacy and bilateral trade. Notably, this included leading the British government's climate strategy in Minas Gerais when the United Kingdom held the presidency of COP26. His efforts culminated with an unprecedented cooperation between the UK and the government of Minas Gerais, and key cities in the region. His efforts culminated in Minas Gerais becoming the first state in Latin America to formalize its commitment to decarbonization and to join the UN campaign “Race to Zero”1.

Key Points: 
  • Verde to host Investor Day on October 16, 2023
    SINGAPORE, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Verde AgriTech Ltd (TSX: “NPK”) ("Verde” or the “Company”) is pleased to announce Lucas Brown as the new Vice President of Corporate Development.
  • "We're thrilled to welcome Mr Brown as our new Vice President of Corporate Development.
  • "I am incredibly excited to join Verde AgriTech, a Company I have been following for several years and whose ESG values align with my own.
  • The invitation to join Verde to lead this innovative decarbonization project was impossible to refuse," stated Mr Brown.

TurnkeyZRG Expands to Europe with the Hire of George Williams

Retrieved on: 
星期三, 十月 4, 2023

Based in London, Williams brings over 15 years of executive search experience in sports and entertainment and will lead TurnkeyZRG’s fast-growing practice in Europe.

Key Points: 
  • Based in London, Williams brings over 15 years of executive search experience in sports and entertainment and will lead TurnkeyZRG’s fast-growing practice in Europe.
  • George Williams is ahead of the curve, with deep experience across European clients, and U.S. clients abroad, delivering bespoke, smarter, cutting-edge placements,” said Len Perna, Chairman and CEO of TurnkeyZRG.
  • Prior to joining TurnkeyZRG, Williams was a Partner at Savannah Group, where he led the Sport and Media Practice across Europe.
  • George Williams holds a BA (Hons) degree in Sociology from Newcastle University.

ViroCell Expands Business Development Team to Support Next Phase of Growth

Retrieved on: 
星期三, 十月 4, 2023

Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCell from roles across CMDO businesses focused on cell and gene therapy.

Key Points: 
  • Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCell from roles across CMDO businesses focused on cell and gene therapy.
  • Joining ViroCell to accelerate business growth across Europe, Makis brings over 25 years of biopharmaceutical experience marked by contributions to the development of innovative biotechnology products and successful businesses.
  • Most recently, he was Director of Business Development at Catalent Cell and Gene Therapy (“Catalent”, NYSE: CTLT), a CDMO specialising in advanced therapeutics.
  • Before this, Makis worked at the UK’s Cell and Gene Therapy Catapult as a Business Development Manager.

Verde to Present at the LD Micro Main Event XVI

Retrieved on: 
星期二, 十月 3, 2023

The presentation will take place on Wednesday, October 04, 2023, at 9:30am PT

Key Points: 
  • Verde currently operates two production plants, along with a biomanufacturing facility for producing fertilizers with microorganism input additives.
  • This establishes the Company as Brazil's largest potash producer by capacity, with an installed production capacity of 3.00 million tonnes per year.
  • With its installed annual production capacity of 3.00 million tonnes5, Verde expects to capture and offset up to 0.36 million tonnes of CO2 per year.
  • Verde AgriTech will host an Investor Day on Monday, October 16, 2023, at 11:00 AM Eastern Time.

Astarte Medical and Tiny Health Join Forces to Optimize Gut Health for Vulnerable Preterm Infants

Retrieved on: 
星期四, 九月 21, 2023

YARDLEY, Pa. and AUSTIN, Texas, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Astarte Medical, a leading pediatric clinical intelligence company, is forming a joint venture with Tiny Health, makers of gut microbiome tests for babies and expecting parents. The partners have agreed to develop a clinical-facing technology solution to support gut health for preterm and critically ill infants receiving care in the neonatal ICU.

Key Points: 
  • The partners have agreed to develop a clinical-facing technology solution to support gut health for preterm and critically ill infants receiving care in the neonatal ICU.
  • "By partnering with Astarte Medical, we're extending our solution to support infants and families at their most vulnerable time.
  • In a previous multi-center microbiome study, Astarte Medical identified six gut community types among nearly 300 preterm infants born under 34 weeks gestational age.
  • Tiny Health will offer NICU parents the option to test their infants post-discharge to extend the understanding of the maturity patterns of infants born preterm.